Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

Pfizer narrows review for Zyrtec

Published on .

Pfizer is believed to have narrowed the list of agencies in contention for its estimated $75 million Zyrtec anti-allergy drug account. Deutsch; Kirshenbaum, Bond & Partners; Merkley Newman Harty; Ogilvy & Mather Worldwide; and McCann-Erickson Worldwide are all believed to be finalists. A Pfizer spokeswoman declined comment.

Copyright June 1999, Crain Communications Inc.

Most Popular
In this article: